Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab183420-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$109.90
|
|
|
Ab183420-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$509.90
|
|
|
Ab183420-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,279.90
|
|
|
Ab183420-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,049.90
|
|
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Drozitumab (anti-TNFRSF10B) - Primary antibody, specific to TNFRSF10B, >95% (SDS-PAGE&SEC), high purity, Human IgG1, AGONIST of Tumor necrosis factor receptor superfamily member 10B agonist |
|---|---|
| Synonyms | Fas like protein antibody | Apoptosis inducing protein TRICK2A/2B antibody | Apoptosis inducing receptor TRAIL R2 antibody | CD262 antibody | CD262 antigen antibody | Cytotoxic TRAIL receptor 2 antibody | Death domain containing receptor for TRAIL/Apo 2L |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | TNFRSF10B |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | AGONIST |
| Mechanism of action | AGONIST of Tumor necrosis factor receptor superfamily member 10B agonist |
| Product Description |
Drozitumab (anti-TNFRSF10B) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab (anti-TNFRSF10B) has potent antitumor activity against rhabdomyosarcoma. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | lambdaC2 |
| SDS-PAGE | 29.1 kDa (Light Chain) & 51.8 kDa (Heavy Chain), under reducing conditions; 207.6 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% (SDS-PAGE&SEC) |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 912628-39-8 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Drozitumab (anti-TNFRSF10B) (Ab183420) - ELISA
Immobilized Recombinant Human Human TRAIL R2/TNFRSF10B protein (rp176693) at 1.0 μg/mL can bind Drozitumab (anti-TNFRSF10B) (Ab183420) with the EC50 of 14.55 ng/mL.
Drozitumab (anti-TNFRSF10B) (Ab183420) - SEC
The purity of Drozitumab (anti-TNFRSF10B) (Ab183420) is more than 95% verified by HPLC.
Starting at $109.90
Starting at $69.90
Starting at $99.90